WO2011135581A3 - Pharmaceutical compositions of dronedarone - Google Patents
Pharmaceutical compositions of dronedarone Download PDFInfo
- Publication number
- WO2011135581A3 WO2011135581A3 PCT/IN2011/000270 IN2011000270W WO2011135581A3 WO 2011135581 A3 WO2011135581 A3 WO 2011135581A3 IN 2011000270 W IN2011000270 W IN 2011000270W WO 2011135581 A3 WO2011135581 A3 WO 2011135581A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dronedarone
- pharmaceutical compositions
- composition
- devoid
- surfactant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
A pharmaceutical composition is disclosed, said composition comprising dronedarone or pharmaceutically acceptable salts thereof, wherein said composition is devoid of surfactant.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1354/MUM/2010 | 2010-04-28 | ||
IN1354MU2010 | 2010-04-28 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011135581A2 WO2011135581A2 (en) | 2011-11-03 |
WO2011135581A8 WO2011135581A8 (en) | 2011-12-29 |
WO2011135581A3 true WO2011135581A3 (en) | 2012-04-12 |
Family
ID=44629169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2011/000270 WO2011135581A2 (en) | 2010-04-28 | 2011-04-26 | Pharmaceutical compositions of dronedarone |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011135581A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2654730B1 (en) * | 2010-12-24 | 2016-11-23 | KRKA, d.d., Novo mesto | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts |
FR2977495B1 (en) * | 2011-07-07 | 2014-03-07 | Sanofi Sa | PHARMACEUTICAL COMPOSITION AND SOLID GALENIC FORM WITH HIGH DRONEDARONE CONTENT AND PROCESS FOR PREPARING THE SAME |
WO2013024411A1 (en) | 2011-08-12 | 2013-02-21 | Lupin Limited | Co-milled formulation of dronedarone |
US20150017242A1 (en) | 2012-02-20 | 2015-01-15 | Lupin Limited | Bilayer Tablet of Dronedarone |
CN103565763B (en) * | 2012-07-26 | 2016-09-07 | 山东新时代药业有限公司 | A kind of Dronedarone hydrochloride tablet and preparation method thereof |
WO2016120299A1 (en) * | 2015-01-28 | 2016-08-04 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Orally disintegrating formulations of dronedarone |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985915A (en) * | 1996-03-18 | 1999-11-16 | Sanofi | Use of antiarrhythmic compounds in the prevention of post-infarction mortality |
US20070243257A1 (en) * | 2004-09-17 | 2007-10-18 | Sanofi-Aventis | Pharmaceutical composition comprising a solid dispersion with a polymer matrix containing a continuous polydextrose phase and a continuous phase of a polymer other than polydextrose |
US7323493B1 (en) * | 1997-06-23 | 2008-01-29 | Sanofi-Aventis | Solid pharmaceutical composition containing benzofuran derivatives |
CN101152154A (en) * | 2006-09-29 | 2008-04-02 | 北京德众万全药物技术开发有限公司 | Hydrochloric acid dronedarone medicinal compositions for oral use and method for preparing the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2665444B1 (en) | 1990-08-06 | 1992-11-27 | Sanofi Sa | AMINO-BENZOFURAN, BENZOTHIOPHENE OR INDOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING THEM. |
KR20100135909A (en) | 2008-04-17 | 2010-12-27 | 사노피-아벤티스 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
-
2011
- 2011-04-26 WO PCT/IN2011/000270 patent/WO2011135581A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985915A (en) * | 1996-03-18 | 1999-11-16 | Sanofi | Use of antiarrhythmic compounds in the prevention of post-infarction mortality |
US7323493B1 (en) * | 1997-06-23 | 2008-01-29 | Sanofi-Aventis | Solid pharmaceutical composition containing benzofuran derivatives |
US20070243257A1 (en) * | 2004-09-17 | 2007-10-18 | Sanofi-Aventis | Pharmaceutical composition comprising a solid dispersion with a polymer matrix containing a continuous polydextrose phase and a continuous phase of a polymer other than polydextrose |
CN101152154A (en) * | 2006-09-29 | 2008-04-02 | 北京德众万全药物技术开发有限公司 | Hydrochloric acid dronedarone medicinal compositions for oral use and method for preparing the same |
Non-Patent Citations (2)
Title |
---|
ANONYMOUS: "Highlights of prescribing information + Full Prescribing information for Multaq", INTERNET CITATION, 1 July 2009 (2009-07-01), XP055004918, Retrieved from the Internet <URL:http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf> [retrieved on 20110816] * |
DATABASE WPI Week 200872, Derwent World Patents Index; AN 2008-M14521, XP002668798 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011135581A8 (en) | 2011-12-29 |
WO2011135581A2 (en) | 2011-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011012816A3 (en) | Pharmaceutical formulation | |
WO2010092090A3 (en) | Novel salts of sitagliptin | |
WO2011131943A3 (en) | Pharmaceutical compositions | |
WO2010114405A3 (en) | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same | |
HK1186978A1 (en) | Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative | |
WO2011057262A3 (en) | Treatment of infections with tp receptor antagonists | |
MY162411A (en) | Crystalline forms of a macrolide, and uses therefor | |
WO2010117738A3 (en) | Solid state forms of sitagliptin salts | |
WO2012025944A3 (en) | Sitagliptin, salts and polymorphs thereof | |
WO2011135581A3 (en) | Pharmaceutical compositions of dronedarone | |
WO2012085927A3 (en) | Tadalafil compositions | |
WO2011076212A3 (en) | Processes for the manufacture of a pharmaceutically active agent | |
MX354691B (en) | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]th iophene-2-carboxamide hydrochloride monohydrate. | |
WO2011015882A3 (en) | Anhydrate of triotropium bromide | |
WO2011079193A3 (en) | Preparation of bendamustine and its salts | |
WO2012101653A3 (en) | Modified release pharmaceutical compositions memantine | |
WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
WO2010049449A3 (en) | Novel salts of sunitinib | |
WO2012140596A8 (en) | Glycoside derivatives and uses thereof | |
WO2010123545A3 (en) | Angiogenesis inhibitors | |
IN2012DN04868A (en) | ||
WO2011135580A3 (en) | Pharmaceutical compositions of sirolimus | |
WO2012029074A3 (en) | Pharmaceutical compositions of linezolid | |
WO2012018791A3 (en) | Preparation of prasugrel hydrochloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11736459 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11736459 Country of ref document: EP Kind code of ref document: A2 |